Search

Valbenazine

The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910] … [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively.

Diloxanide furoate

Ibrutinib

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. … April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US.

Succinic acid

A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters.

Omidubicel

[A258938,A258943,L46048] This type of cell therapy benefits patients that require stem cell transplantation as a treatment for blood cancers for whom a related or unrelated donor cannot be found due to … In this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching.

Sapropterin

Sapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa ...

Terconazole

[A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. … Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a _triazole ketal derivative_.

PF-06459988

PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).

Meningococcal polysaccharide vaccine group Y

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

Pirtobrutinib

[A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib. … Although the mechanisms of resistance to covalent BTK inhibitors have not been fully elucidated, it appears that the presence of Cys481 mutations is the most common reason for resistance to covalent BTK